BIOMARKERS IN THE ACUTE RESPIRATORY DISTRESS SYNDROME: PAST, PRESENT, AND FUTURE

Area of Science:

• Critical care medicine
• Pulmonology
• Biomarker research

Background:

• Acute Respiratory Distress Syndrome (ARDS) affects over 3 million globally each year, representing 10% of ICU admissions.
• Despite advances, ARDS lacks specific treatments, leading to high mortality rates.
• The COVID-19 pandemic highlighted the urgent need for ARDS pathogenesis understanding and therapeutic interventions.

Purpose of the Study:

• To review the role of biomarkers in understanding ARDS pathogenesis.
• To identify barriers to developing specific ARDS treatments.
• To leverage past biomarker studies to accelerate therapeutic development.

Main Methods:

• Review of existing literature on ARDS epidemiology, pathogenesis, and biomarker studies.
• Analysis of factors hindering therapeutic intervention development.
• Examination of biomarker measurement's contribution to ARDS knowledge.

Main Results:

• Biomarker measurements have elucidated barriers to ARDS treatment, including prediction, definition, diagnostic markers, patient heterogeneity, and clinical care impact.
• Biomarker studies offer valuable insights into ARDS pathogenesis.
• Past research provides a foundation for addressing ARDS challenges.

Conclusions:

• Biomarkers are essential for understanding ARDS and overcoming treatment development barriers.
• Further biomarker research is critical for advancing ARDS therapeutics.
• Leveraging existing knowledge can expedite the development of life-saving interventions for ARDS.